ArticleClinical and experimental medicine2025
HNF4A promotes tumor progression in gastric cancer by transcriptional activation of KIF2C.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of HNF4α in adenocarcinoma.Biochemical Society transactions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatocyte nuclear factor 4A (HNF4A) is a core transcription factor that plays an important role in tumor progression. However, the regulatory mechanisms in gastric cancer remain unclear. In this study, we employed a bioinformatics-driven approach and combined it with cellular and animal experiments to investigate the regulatory mechanisms of HNF4A in gastric cancer. We identified kinesin family member 2C (KIF2C) as a novel downstream target of HNF4A and observed that both HNF4A and KIF2C were significantly upregulated in gastric cancer tissues. Knockdown of HNF4A or KIF2C inhibited the proliferation, migration, and invasion abilities of gastric cancer cells, while overexpression of KIF2C rescued these abilities of sh-HNF4A in gastric cancer cells. Mechanistically, HNF4A and KIF2C were found to colocalize in the nucleus, with HNF4A directly binding to the KIF2C promoter. Further analysis identified BS2 (-1381 ~ -1368) and BS3 (-715 ~ -700) as the core binding regions. In vivo experiments demonstrated that knockdown HNF4A inhibited tumor growth in BALB/c nude mice, and overexpression of KIF2C promoted tumor growth. In conclusion, HNF4A is an oncogene that promotes the proliferation, migration, and invasion of gastric cancer cells. Our study suggests that HNF4A can transcriptionally activate KIF2C and that the HNF4A-KIF2C axis may be a potential therapeutic target for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.